Loftyrock Investment

GenEdit Inc., founded in 2016 and based in Berkeley, California, focuses on advancing gene therapy through its innovative genome editing tools, particularly the CRISPR/Cas9 system. The company aims to address the challenges associated with gene therapy delivery by utilizing its proprietary NanoGalaxy™ platform, which systematically screens a library of nanoparticles to enhance the safety and efficiency of delivering genetic material to target tissues. GenEdit's technology is designed to facilitate therapeutic gene editing, offering a solution that is easier, faster, and more accurate than traditional methods. This positions GenEdit to potentially enable the treatment of previously incurable genetic diseases, significantly contributing to the future of non-viral, gene editing-based therapeutics.

Galux specializes in molecular design technology aimed at discovering and developing innovative drugs for incurable and rare diseases. The company employs an AI-based drug design platform that integrates artificial intelligence, physics, and chemistry to create a range of biomolecules, including small molecules, peptides, and larger proteins. By focusing on attractive biological targets, Galux's technology assists healthcare professionals in addressing complex medical challenges and advancing treatment options for patients with limited alternatives.